$KDMN News
Last published 1y ago
- 1y agoAVIRLQDAKDMNAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsGlobeNewswireBOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 3y agoMGTXOVIDKDMNOvid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 InhibitorsGlobeNewswireCollaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to
- 3y agoKDMNA Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects - NCT05806567ClinicalTrials.govAUC(0-last)- Parts 1,2, and 3 (victim drugs), AUC(0-inf)- Parts 1,2, and 3 (victim drugs, Tmax- Parts 1, 2, and 3 (victim drugs, belumosudil and belumosudil metabolites), (and 10 more...)
- 4y agoKDMNSafety and Efficacy of Oral Belumosudil in Black or African American Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy - NCT05567406ClinicalTrials.govNumber of participants with treatment emergent adverse events and serious adverse events, Number of participants with clinically significant laboratory abnormalities, Change from baseline in systolic and diastolic blood pressure, (and 18 more...)
- 5y agoKDMNKadmon Provides Business Update and Reports Third Quarter 2021 Financial ResultsACCESS Newswire- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - S
- 5y agoINMKDMNNXTPSENS+1Thinking about buying stock in Nextplay Technologies, Sio Gene Therapies, Kadmon, Senseonics, or InMed Pharmaceuticals?PR NewswireNEW YORK, Oct. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, SIOX, KDMN, SENS, and INM. T
- 5y agoKDMNKadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual MeetingACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced
- 5y agoHTPAJMPKDMNNXUMoore Kuehn Encourages KDMN, NXU, JMP, and HTPA Investors to Contact Law FirmPR NewswireNEW YORK, Sept. 15, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 5y agoADMACOUPGANXKDMN+1Thinking about buying stock in Kadmon Holdings, ADMA Biologics, National CineMedia, Coupa Software, or Gain Therapeutics?PR NewswireNEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KDMN, ADMA, NCMI, COUP, and GANX.
- 5y agoKDMNMSBLKSTT+1European Stocks Slide Most in Three Weeks on Economy, ECB RiskBloomberg
- 5y agoKDMNSanofi to acquire Kadmon to further strengthen growth of transplant businessGlobeNewswireSanofi to acquire Kadmon to further strengthen growth of transplant business Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
- 5y agoKDMNSanofi To Acquire Kadmon To Further Strengthen Growth of Transplant BusinessACCESS NewswireAdds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy PARIS, FRANCE and N
- 5y agoKDMNKadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)ACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment to prescribed patients in the United States. REZURO
- 5y agoKDMNKadmon Provides Business Update and Reports Second Quarter 2021 Financial ResultsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The recent U.S. FDA approval of REZUROCK marked a transform
- 5y agoKDMNKadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell TransplantationACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Gui
- 5y agoKDMNKadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)ACCESS Newswire- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NAS
- 5y agoKDMNU.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)ACCESS Newswire- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET - NEW YORK,
- 5y agoZIMCCIVFSRRIDE+8Cramer's lightning round: Keystone shut down makes these stocks buysCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 5y agoKDMNKadmon to Present at Upcoming Investor ConferencesACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: Jefferies Virtual Healthcare C
- 5y agoKDMNLHDXMBIIMOXC+1Thinking about buying stock in Marrone Bio Innovations, Village Farms, Moxian, Lucira Health, or Kadmon Holdings?PR NewswireNEW YORK, May 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBII, VFF, MOXC, LHDX, and KDMN. To
- 5y agoKDMNKadmon to Present Initial Safety Data from Phase 1 Study of KD033 at the 2021 American Society of Clinical Oncology Annual MeetingACCESS Newswire- Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY / ACCESSWIRE / May 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced initial safety dat
- 5y agoKDMNKadmon Provides Business Update and Reports First Quarter 2021 Financial ResultsACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021. "We continue to ramp up commercial launch preparation activities
- 5y agoKDMNKadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical OncologyACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical Oncology. A New Drug Application (NDA) for belumosudil is currently under Priority Review by the U.S Food an ...
- 5y agoKDMNKadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic SclerosisACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs.
- 5y agoKDMNKadmon Announces Trial-In-Progress Poster on KD033 at the 2021 American Association for Cancer Research Annual MeetingACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place virtually April 10 - 15, 2021.
- 5y agoKDMNKadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host DiseaseACCESS NewswireNEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD). In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User ...
- 5y agoKDMNKadmon Provides Business Update and Reports Fourth Quarter 2020 Financial ResultsACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020.
- 5y agoKDMNKadmon Announces Appointment of Dr. Simon Cooper as Chief Medical OfficerACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the ...
- 5y agoKDMNKadmon to Present at Upcoming Investor ConferencesACCESS NewswireNEW YORK, NY / ACCESSWIRE / February 24, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present and host investor meetings at the following virtual investor conferences:
- 5y agoKDMNMGTXGraviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing TidePR NewswireGraviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide...
- 5y agoKDMNKadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment OptionACCESS NewswireKadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, which includes the full exercise of the $40 million over-allotment option. The initial conversion pr ...
- 5y agoKDMNKadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call TransactionsACCESS NewswireKadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. This offering was upsized from the previously announced offering of $150 million of aggregate principal amount ...
- 5y agoKDMNKadmon Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call TransactionsACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today announced its intent to offer, subject to market conditions and other factors, $150 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Kadmon also expects to grant the initial purchaser of the Notes ...
- 5y agoKDMNKadmon Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor ResponseACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of preclinical data demonstrating that KD033, the Company's anti-PD-L1/IL-15 fusion protein, achieved robust anti-tumor responses in multiple syngeneic tumor models. The data were published in Molecular Cancer Therapeutics, an American Association for Cancer Research (AACR) journal. KD033 is currently being evaluated in a Phase 1 ...
- 5y agoKDMNKadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual MeetingACCESS Newswire- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively -
- 5y agoKDMNKadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host DiseaseACCESS Newswire- FDA Grants Priority Review and Sets PDUFA Date of May 30, 2021 - - Application Being Evaluated Under FDA's Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs -
- 5y agoKDMNKadmon to Host Virtual Key Opinion Leader Event at the 62nd ASH Annual MeetingACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the Company will host a virtual key opinion leader event on Sunday, December 6, 2020 at 11:15 a.m. PT (2:15 p.m. ET) at the 62nd American Society of Hematology (ASH) Annual Meeting.
- 6y agoKDMNKadmon to Present at Upcoming Investor ConferencesACCESS NewswireNEW YORK, NY / ACCESSWIRE / November 12, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences:
- 6y agoKDMNKadmon Provides Business Update and Reports Third Quarter 2020 Financial ResultsACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2020.
- 6y agoKDMNKadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual MeetingACCESS NewswireKadmon Holdings, Inc. (NASDAQ:KDMN) announced today that 12-month data from ROCKstar (KD025-213), the ongoing pivotal trial of belumosudil (KD025) for the treatment of chronic graft-versus-host disease (cGVHD), have been selected for oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5 - 8, 2020.
- 6y agoKDMNKadmon Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer's 35th Anniversary Annual MeetingACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) announced today it will present preclinical data on its anti-PD-1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer's (SITC 2020) 35th Anniversary Annual Meeting, taking place virtually November 9 - 14, 2020.
- 6y agoKDMNKadmon to Transfer U.S. Stock Exchange Listing to NasdaqACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) announced today that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market ("Nasdaq"). The Company will retain the "KDMN" ticker with trading on the Nasdaq expected to begin on October 26, 2020.
- 6y agoKDMNKadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host DiseaseACCESS NewswireApplication Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program
- 6y agoKDMNFDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic SclerosisACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of systemic sclerosis (SSc). SSc is a chronic immune disorder characterized by fibrosis of the skin and internal organs, affecting approximately 75,000 to ...
- 6y agoKDMNKadmon to Present at Upcoming Investor ConferencesACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences:
- 6y agoKDMNKadmon Announces Appointment of Nancy Miller-Rich to Board of DirectorsACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Nancy Miller-Rich to its Board of Directors.
- 6y agoKDMNKadmon Provides Business Update and Reports Second Quarter 2020 Financial ResultsACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2020.
- 6y agoKDMNKadmon Doses First Patient in Phase 1 Clinical Trial of KD033, an Anti-PD-L1/IL-15 Fusion Protein, in Adults with Metastatic or Locally Advanced Solid TumorsACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors. KD033 is a novel immunotherapy designed to stimulate innate and adaptive immune responses directed to the tumor microenvironment.
- 6y agoKDMNKadmon to Present at the Raymond James 2020 Virtual Human Health Innovation ConferenceACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Raymond James 2020 Virtual Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET.
- 6y agoKDMNKadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market FacilityACCESS NewswireKadmon Holdings, Inc. (NYSE:KDMN) today announced that it has raised gross proceeds of $50.0 million through its At-The-Market (ATM) facility, including participation based on interest received from existing shareholders and new healthcare specialist institutional investors. The Company sold approximately 11.1 million shares at then-prevailing market prices. With the closing of this transaction, t ...